Sachin Patel to acquire 5.25 lakh shares in Gujarat Themis Biosyn

Promoter Sachin D. Patel has disclosed an intention to acquire up to 5,25,000 equity shares of Gujarat Themis Biosyn Limited from Pharmaceutical Business Group (India) Limited. The proposed acquisition, valued at up to ₹20 Crores, will take place between July 21, 2026, and July 31, 2026, at a price of ₹382 per equity share. This inter-se transfer among the promoter group will increase Patel's stake to 2.77% from the current 2.29%, while the seller's holding will reduce to 46.54% from 47.02%.

The transaction is being conducted under Regulation 10(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The acquisition is exempt from the requirement to make an open offer under Regulation 10(1)(a)(ii). The price of ₹382 per share is within the permissible limit, not exceeding 25% of the volume weighted average market price of ₹380.37 per equity share calculated over the 60 trading days preceding the notice.

Sachin D. Patel confirmed that both the transferor and transferee have complied with applicable disclosure requirements in Chapter V of the SEBI (SAST) Regulations, 2011, during the three years prior to the proposed acquisition. The acquirer also declared that all conditions specified under Regulation 10(1)(a)(ii) regarding exemptions have been duly complied with.

A previous disclosure made on July 1, 2026, regarding the same transaction was disregarded as it could not be acted upon within the stipulated period. The new disclosure supersedes the earlier intimation. The actual number of shares acquired may be less than the proposed 5,25,000 equity shares.

Shareholding Details

Entity	Shares Before Transaction	% Before	Shares After Transaction	% After
Acquirer (Dr. Sachin Patel)	24,97,200	2.29%	30,22,200	2.77%
Seller (Pharmaceutical Business Group (India) Limited)	5,12,40,000	47.02%	5,07,15,000	46.54%

Transaction Key Points

Acquirer: Sachin D. Patel (Promoter)
Target: Gujarat Themis Biosyn Limited
Seller: Pharmaceutical Business Group (India) Limited
Shares: Up to 5,25,000 equity shares (0.50%)
Price: ₹382 per equity share
Period: July 21, 2026 to July 31, 2026

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.44%	+1.09%	-3.82%	+3.93%	+2.60%	+52.14%

Pharmaceutical Business Group (India) Limited has disclosed an indirect encumbrance over 5,12,40,000 equity shares of Gujarat Themis Biosyn Limited , representing 47.02% of the target company's equity share capital. The encumbrance follows the creation of a pledge and a non-disposal undertaking by Vividhmargi Investments Private Limited (VIPL) over shares held in Pharmaceutical Business Group (India) Limited. As Pharmaceutical Business Group (India) Limited is a promoter group entity, this action results in an indirect charge on the shares it holds in Gujarat Themis Biosyn Limited.

The disclosure was submitted to BSE Limited and National Stock Exchange of India Limited on July 3, 2026, in compliance with Regulation 31 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. VIPL executed a Pledge Agreement-cum-Non-Disposal Undertaking on June 28, 2026, in favour of CTL Trusteeship Limited, acting as the Debenture Trustee. This agreement is connected to a Debenture Trust Deed dated June 25, 2026.

The underlying encumbrance involves a pledge over 25,24,245 equity shares, constituting 51% of the issued and paid-up share capital of Pharmaceutical Business Group (India) Limited. Additionally, a non-disposal undertaking was created over 21,57,855 equity shares, representing 47.98% of the promoter group entity's capital. Consequently, the 5,12,40,000 shares held by Pharmaceutical Business Group (India) Limited in Gujarat Themis Biosyn Limited are now indirectly encumbered.